Tradestie Institutional Equity Comparison Engine

LYRA vs BAX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BAX Overall Edge

BAX Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Baxter International Inc. (BAX) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, LYRA trades at N/M Forward P/E with -25032.0% operating margin (-87.2% YoY revenue) versus BAX at 12.5x Forward P/E and 7.6% operating margin (+5.0% YoY). In options structure, LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BAX sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner BAX
LYRA N/M vs BAX 12.5x Fwd P/E
Growth & Margin Winner BAX
Op Margin -25032.0% vs 7.6% ยท YoY -87.2% vs +5.0%
Momentum & Technical Winner BAX
1Y -94.3% vs +39.9% ยท 52W Pos 1% vs 71%
Options & Structure Winner BAX
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (5th %ile IV)
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
1M Return -62.5%
1Y Return -94.34%
Forward P/E N/M
Unified AI Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
BAX NYSE
Baxter International Inc.
Surgical & Medical Instruments & Apparatus
$25.83
+1.14% 1D
Market Cap $13.4B
1M Return +3.36%
1Y Return +39.85%
Forward P/E 12.5x
Unified AI Score
46.5 / 100 HOLD
Tech 47.0 Fund 56.0 Flow 71.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LYRA -94.34% BAX +39.85% Spread: +79.61 pp (BAX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LYRA Revenue BAX Revenue LYRA Op. Margin BAX Op. Margin Margin Edge
FY2018 N/A $11.1B N/A 14.3% BAX
FY2019 N/A $11.4B N/A 15.6% BAX
FY2020 N/A $11.7B N/A 13.8% BAX
FY2021 $0M $12.2B -15303.5% 11.1% BAX
FY2022 $0M $10.1B -4131.0% -28.3% BAX
FY2023 $0M $10.4B -4308.1% 6.8% BAX
FY2024 $0M $10.6B -6280.8% 0.1% BAX
FY2025 $0M $11.2B -7794.5% -2.7% BAX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LYRA (2) vs BAX (8)
Institutional Metric LYRA BAX Criterion Row Winner
Market Capitalization Scale $2.3M $13.4B Larger Scale BAX
Trailing P/E Ratio Valuation N/M 12.2x Lower Multiple BAX
Forward P/E Ratio Valuation N/M 12.5x Lower Multiple BAX
Revenue Growth (YoY) Growth -87.2% +5.0% Higher Growth BAX
Operating Margin (TTM) Profitability -25032.0% 7.6% Higher Margin BAX
Net Profit Margin Profitability 0.0% -6.2% Higher Margin LYRA
Return on Equity (ROE) Capital Efficiency -404.5% -9.0% Higher ROE BAX
52-Week Range Position Momentum 1% ($0โ€“$38) 71% ($16โ€“$30) Stronger Trend BAX
Beta / 30D Volatility Risk Regime 0.33ฮฒ ยท 248% Vol 0.95ฮฒ ยท 47% Vol Lower Realized Risk BAX
Unified Institutional Score Composite Signal 52.2 / 100 (HOLD) 46.5 / 100 (HOLD) Higher Composite LYRA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LYRA vs BAX Buy Guide
LYRA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LYRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BAX CONSOLIDATION
74d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live BAX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LYRA nor BAX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.